Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul-Aug;32(4):312-319.
doi: 10.4103/ijn.ijn_234_21. Epub 2022 May 20.

Two Decades Outcomes of Posttransplant Immunoglobulin A Nephropathy in Live Donor Renal Transplantation

Mudit Khurana  1 , Narayan Prasad  1 , Manas Behera  1 , Monika Yachha  1 , Ravi Kushwaha  1 , Vinita Agarwal  1 , Dharmendra Bhadauria  1 , Anupama Kaul  1 , Manas Patel  1 , Manoj Jain  1
Affiliations

Two Decades Outcomes of Posttransplant Immunoglobulin A Nephropathy in Live Donor Renal Transplantation

Mudit Khurana et al. Indian J Nephrol. 2022 Jul-Aug.

Abstract

Background: The data on long-term outcomes of posttransplant immunoglobulin A nephropathy (IgAN) are confounding and vary with geography and ethnicity worldwide. We aimed to study the long-term graft outcomes of patients with posttransplant IgAN in the northern Indian cohort.

Methods: The long-term graft outcomes of 51 live donor renal transplant recipients with biopsy-proven posttransplant IgAN (recurrence/de novo) were analyzed. The risk factors for graft failure in the posttransplant IgA groups were analyzed using the Cox regression analysis.

Results: Out of the total of 51 patients who had posttransplant IgAN, 40 patients had a biopsy-proven native kidney IgAN. The mean duration of the clinical presentation of posttransplant IgAN was 62.4 months (5.2 years) posttransplant. Proteinuria at the time of biopsy was 3.03 ± 2.2 g/day, and 41.2% had proteinuria of more than 3 g/day at the time of biopsy. The estimated 1, 5, 10, and 20 years patient survival was 98%, 95.4%, 75.9%, and 25.2%, respectively, and the estimated 1, 5, 10, and 20 years graft survival was 98%, 88.5%, 44.6%, and 11.9%, respectively, in patients who had posttransplant IgA. Many of the traditional risk factors associated with progression in native kidney IgAN, such as the degree of proteinuria, Oxford MEST (mesangial and endocapillary hypercellularity, segmental sclerosis, and interstitial fibrosis/tubular atrophy) scoring, recipient's age, and sex were not predictive of early graft failure among patients with posttransplant IgAN. In our cohort, the only significant graft failure predictor was serum creatinine at 5 years. Chronic antibody-mediated rejection (ABMR) was seen in 21.6% of patients with posttransplant IgAN. Whether this coexistence of chronic ABMR is an incidental finding or posttransplant IgAN predisposes to chronic ABMR requires further investigation.

Conclusion: Posttransplant IgAN is associated with poor long-term graft outcomes in live donor renal transplants. Proteinuria and MEST scoring were not predictive of graft failure in living donor posttransplant IgAN.

Keywords: IgA nephropathy; outcomes; recurrence; renal transplantation.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier survival analysis showing patient survival
Figure 2
Figure 2
Kaplan–Meier survival analysis showing death-noncensored graft survival
Figure 3
Figure 3
Kaplan–Meier survival analysis showing death-censored graft survival
Figure 4
Figure 4
Kaplan–Meier survival analysis showing death-censored graft survival in posttransplant IgAN with and without chronic antibody-mediated rejection
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Levy M, Berger J. Worldwide perspective of IgA nephropathy. Am J Kidney Dis. 1988;12:340–7. - PubMed
    1. D'Amico G. The commonest glomerulonephritis in the world: GA nephropathy. Q J Med. 1987;64:709–27. - PubMed
    1. Berger J, Noël LH, Nabarra B. Recurrence of mesangial IgA nephropathy after renal transplantation. Contrib Nephrol. 1984;40:195–7. - PubMed
    1. Kim YS, Moon JI, Jeong HJ, Kim MS, Kim SI, Choi KH, et al. Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy. Transplantation. 2001;71:233–8. - PubMed
    1. Andresdottir MB, Hoitsma AJ, Assmann KJ, Wetzels JF. Favourable outcome of renal transplantation in patients with IgA nephropathy. Clin Nephrol. 2001;56:279–88. - PubMed